

esmo.org

# PRECEPTORSHIP PROGRAMME

## Head & Neck Cancer

Multidisciplinary management, standards of care, therapeutic targets and future perspectives

## HONG KONG

## 16-17 MARCH 2018

Co-Chairs Anthony Tak Cheung Chan, HK Jean-Pascal Machiels, BE



## ESMO PRECEPTORSHIP PROGRAMME HEAD & NECK CANCER

Multidisciplinary management, standards of care, therapeutic targets and future perspectives

#### Hong Kong 16-17 March 2018

**CO-CHAIRS:** Anthony Tak Cheung Chan, Hong Kong Jean-Pascal Machiels, Belgium

SPEAKERS:

Victor Ho-Fun Lee, Hong Kong Brigette Ma, Hong Kong Sandra Nuyts, Belgium Christian Simon, Switzerland Joseph Wee, Singapore John Kong Sang Woo, Hong Kong

#### **LEARNING OBJECTIVES**

- To understand epidemiology, aetiology and molecular biology of nasopharyngeal cancer and squamous cell carcinoma of the head and neck (HNSCC)
- To understand multidisciplinary management and treatment of head and neck cancer
- To learn about advances in the treatment and novel targets in head and neck cancer

#### ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

Merck

#### ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



#### **ORGANISATION AND CONTACTS**

ESMO Head Office Education Department Via Luigi Taddei 4 6962 Lugano - Viganello Switzerland Email: courses@esmo.org www.esmo.org



## Friday, 16 March 2018

| 09:00-09:15<br>15'  | Welcome and introduction  | Anthony T. C. Chan, HK<br>Jean-Pascal Machiels, BE        |
|---------------------|---|---|
| 09:15-11:15<br>120' | SESSION 1 - Part 1<br>Nasopharyngeal cancer                                       | Co-Chairs: Anthony T. C. Chan, HK<br>Joseph Wee, SG       |
| 30'                 | Management of localized disease   | Joseph Wee, SG  |
| 30'                 | Epidemiology, diagnosis and work-up   | John K. S. Woo, HK  |
| 30'                 | Management of metastatic disease and salvage treatment                            | Anthony T. C. Chan, HK                                    |
| 30'                 | Molecular biology and biomarkers  | Brigette Ma, HK   |
| 11:15-11:45         | Coffee break  |   |
| 11:45-12:45<br>60'  | SESSION 1 - Part 2<br>Nasopharyngeal cancer                                       | Co-Chairs: Anthony T. C. Chan, HK<br>Joseph Wee, SG       |
| 4x15'               | 4 x Participants clinical case discussion   | Faculty   |
| 12:45-13:45         | Lunch   |   |
| 13:45-15:30<br>105' | SESSION 2 - Part 1<br>Squamous cell carcinoma                                     | Co-Chairs: Victor HF. Lee, HK<br>Jean-Pascal Machiels, BE |
| 60'                 | Indications and techniques of surgery for the primary treatment of HNSCC          | Christian Simon, CH                                       |
| 45'                 | Epidemiology, anatomy and work-up   | Victor HF. Lee, HK  |
| 15:30-16:00         | Coffee break  |   |
| 16:00-18:00<br>120' | SESSION 2 - Part 2<br>Squamous cell carcinoma                                     | Co-Chairs: Victor HF. Lee, HK<br>Jean-Pascal Machiels, BE |
| 60'                 | Indications and modalities of radiation or CRT for local and locoregional disease | Sandra Nuyts, BE  |
| 4x15'               | 4 x Participants clinical case discussion   | Faculty   |
| 19:30               | Dinner  |   |

### Saturday, 17 March 2018

| 08:30-10:30<br>120' | SESSION 3 - Part 1<br>Precision medicine for head and neck cancer   | Co-Chairs: Sandra Nuyts, BE<br>Brigette Ma, HK |
|---------------------|---|--|
| 30'                 | Molecular biology and The Cancer Genome Atlas (TCGA) data   | Jean-Pascal Machiels, BE                       |
| 30'                 | Relapsing HNSCC (salvage treatment, systemic treatment and immunotherapy)                                       | Jean-Pascal Machiels, BE                       |
| 30'                 | Treatment specificities of Human Papillomavirus (HPV)-induced oropharyngeal cancer: The surgeon's point of view | Christian Simon, CH                            |
| 30'                 | Treatment specificities of HPV-induced oropharyngeal cancer:<br>The radiation oncologist's point of view        | Sandra Nuyts, BE                               |

| 10:30-11:00        | Coffee break  |  |
|--------------------|---|--|
| 11:00-12:00<br>60' | SESSION 3 - Part 2<br>Precision medicine for head and neck cancer | Co-Chairs: Sandra Nuyts, BE<br>Brigette Ma, HK     |
| 4x15'              | 4 x Participants clinical case discussion                         | Faculty  |
| 12:00-12:15<br>15' | Conclusion and farewell   | Anthony T. C. Chan, HK<br>Jean-Pascal Machiels, BE |
| 12:15-13:15        | Lunch   |  |

Note: Each 15 minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion

